Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 21st World Congress on Gastrointestinal Cancer /
Latest results from KEYNOTE-181: Pembrolizumab versus chemotherapy as a second-line therapy for advanced oesophageal cancer

3rd - 7th Jul 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.07.19
Views: 879

Prof Jean-Philippe Metges - Centre Hospitalier Régional et Universitaire de Brest, Brest, France

Prof Jean-Philippe Metges speaks to ecancer at ESMO 21st World Congress on Gastrointestinal Cancer about the final results from the KEYNOTE-181 study, in which patients with advanced oesophageal cancer were administered pembrolizumab or chemotherapy as a second-line therapy.

He describes the design of the trial, including the patient population included in the trial and the outcomes assessed.

Prof Metges states that overall survival was improved in patients with adenocarcinoma and squamous cell carcinoma when administered pembrolizumab. Grade 3 - 5 toxicities and patient quality of life were also improved with pembrolizumab. However, no improvement was seen in progression-free survival.

He concludes by emphasising that this could be a new treatment option for patients with adenocarcinoma and squamous cell carcinoma due to the promising results this phase III trial has generated. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation